Blooms | $2,600,000 | (May 21, 2025)
Gravitee | $60,000,000 | (May 21, 2025)
Legora | $80,000,000 | (May 21, 2025)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
FANBASIS | $20,000,000 | (May 21, 2025)
Seeds | $10,000,000 | (May 21, 2025)
Meibel | $7,000,000 | (May 21, 2025)
Coworker.ai | $13,000,000 | (May 21, 2025)
Catena Labs | $18,000,000 | (May 21, 2025)
TrustCloud | $15,000,000 | (May 21, 2025)
AskElephant | $6,000,000 | (May 21, 2025)
Moddule | $1,500,000 | (May 21, 2025)
Miter | $38,000,000 | (May 20, 2025)